DTIL
Precision Biosciences Inc

3,706
Mkt Cap
$64.03M
Volume
170,359.00
52W High
$8.82
52W Low
$3.61
PE Ratio
-0.57
DTIL Fundamentals
Price
$4.98
Prev Close
$4.82
Open
$4.95
50D MA
$5.97
Beta
0.87
Avg. Volume
164,392.52
EPS (Annual)
$1.04
P/B
3.50
Rev/Employee
$636,074.07
Loading...
Loading...
News
all
press releases
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Business Wire·1d ago
News Placeholder
More News
News Placeholder
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
Precision BioSciences, Inc. (Nasdaq: DTIL) (Precision), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet...
Business Wire·10d ago
News Placeholder
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Business Wire·10d ago
News Placeholder
What is HC Wainwright's Forecast for DTIL FY2025 Earnings?
Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) - Investment analysts at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for Precision BioSciences in a research note issued...
MarketBeat·13d ago
News Placeholder
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Business Wire·20d ago
News Placeholder
Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last?
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·1mo ago
News Placeholder
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2025
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Business Wire·1mo ago
News Placeholder
Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Business Wire·1mo ago
News Placeholder
Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains?
Immunome (IMNM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·2mo ago
News Placeholder
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago

Latest DTIL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.